Funded Projects › H2020
PARADIGM · Patients Active in Research and Dialogues for an Improved Generation of Medicines: Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes.
PARADIGM will provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engagement (PE) and demonstrates the ‘return on the engagement’ for all players. Much needed processes and tools for three key decision-making points (research priority setting, design of clinical trials and early dialogue) will be developed by consensus. Building on advances at international level, PARADIGM will integrate the needs, perspectives and expectations of all actors (including vulnerable populations) involved and will also produce a stakeholder-tailored set of metrics to measure the impact of PE.PARADIGM will deliver to the community, recommendations and tools to support the implementation of PE, leveraging pre-existing resources. These will address capacity and capability questions, managing potential conflict of interest, the compensation of individuals and organisations, and the ethics of engagement. A targeted communication, dissemination and engagement strategy will promote the endorsement of the outputs for their integration in existing structures.PARADIGM will develop a strategy for sustaining the long-term implementation of PE resources aimed at structuring and supporting the community. This will be a game-changer, addressing fundamental gaps and creating real assets to ensure the sustainability of the PE ecosystem in the years to come.PARADIGM has a common vision and values-base, and is a highly innovative, consensus-oriented, and experienced consortium, comprising pan-European leaders in patient engagement, academia, SMEs, health professionals, pharmaceutical and biotech companies, pharmaceutical corporate associations, and representatives of competent authorities, all bringing complementary know-how to partner with industry, and a strong commitment to transform patient engagement in Europe.
Consortium · 36 organisations
FORUM DES PATIENTS EUROPEENS
BE · €702,516
EUROPEAN AIDS TREATMENT GROUP EV
DE · €381,750
JANSSEN PHARMACEUTICA NV
BE
VERBAND FORSCHENDER ARZNEIMITTELHERSTELLER EV
DE
H. LUNDBECK AS
DK
SYNERGIST SERVICES
BE
MERCK SHARP & DOHME CORP
US
F. HOFFMANN-LA ROCHE AG
CH
THE SYNERGIST
BE · €543,829
MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN
DE
THE ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY
UK
TEAMIT RESEARCH SL
ES · €73,903
AGENZIA ITALIANA DEL FARMACO
IT · €50,000
AMGEN LIMITED
UK
GRUNENTHAL GMBH
DE
BAYER AKTIENGESELLSCHAFT
DE
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
UK · €621,593
SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT
FR
HEALTH TECHNOLOGY ASSESSMENT INTERNATIONAL SOCIETY
CA
NOVO NORDISK A/S
DK
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER
FR
ELI LILLY AND COMPANY LTD
UK
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL
ES · €399,595
ALEXION SERVICES EUROPE SPRL
BE
ALZHEIMER EUROPE
LU · €248,500
LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED
UK
PFIZER LIMITED
UK
FUNDACIO PRIVADA PER A LA RECERCA I LA DOCENCIA SANT JOAN DE DEU
ES · €176,125
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED
UK
STICHTING VU
NL · €458,438
EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE
BE · €198,000
UCB BIOPHARMA
BE
EURORDIS - RARE DISEASES EUROPE
FR · €463,598
NOVARTIS PHARMA AG
CH
FEDERATION EUROPEENNE D'ASSOCIATIONS ET D'INDUSTRIES PHARMACEUTIQUES
BE
INSTITUTO ARAGONES DE CIENCIAS DE LA SALUD
ES · €181,086
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.